Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03534648 | Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects | PHASE1 | COMPLETED | 16 | — | — | Apr 19, 2018 | Aug 29, 2018 | Sep 18, 2018 | 1 | Belgium |
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 12 hours.
Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 12 hours.
Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)
| Arm | Type | Description |
|---|---|---|
| Effect of PF-05221304 on PF-06865571 PK | EXPERIMENTAL | - |
| Effect of PF-06865571 on PF-05221304 PK | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06865571 administered Day 7-14 | DRUG | PF-06865571 administered Q12hr on Days 7-14 |
| PF-06865571 administered Day 1-14 | DRUG | PF-06865571 administered Q12hr on Day 7-14 |
| PF-05221304 administered Day 1-14 | DRUG | PF-05221304 administered Q12hr on Days 1-14 |
| PF-05221304 administered Day 7-14 | DRUG | PF-05221304 administered Q12hr Days 7-14 |
Inclusion criteria: 1. Healthy female subjects of nonchildbearing potential and/or male subjects. 2. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). Exclusion Criteria 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonar...